{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:21Z","timestamp":1786977981860,"version":"build-2736575974"},"reference-count":115,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":10792,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1982,7,8]]},"abstract":"<jats:p>\n                    Although moxalactam is not, technically speaking, a cephalosporin it is chemically and microbiologically so closely related to those compounds that it can be viewed as a member of the cephalosporin family. Moxalactam has a spectrum of activity that includes both gram positive and gram negative bacteria. Its gram positive activity is less than earlier cephalosporins, but its activity against the Enterobacteriaceae is similar to that of the aminoglycoside family of antibiotics in most comparative studies. Although moxalactam is considerably less active against gram positive bacteria than cefotaxime, another third generation cephalosporin, its higher and more prolonged serum levels probably offset this disadvantage. Compared to cefoperazone, the stability of moxalactam to many types of beta lactamases produced by gram negative bacteria may be advantageous in the therapy of infections caused by hospital\u2010acquired pathogens. Clinical studies suggest that moxalactam can be used for empiric therapy of suspected gram negative infections when Pseudomonas and other non\u2010fermentative bacteria, such as Acinetobacter, are not suspected. Impressive improvements in the survival of patients with gram negative enteric bacillary meningitis have been reported. Although moxalactam, cefotaxime, and cefoperazone have activity against\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    , none of these antibiotics should be used alone as therapy for suspected or proven severe systemic infections caused by this pathogen. Cost is a major problem with all of the new cephalosporin\u2010like antibiotics. While this high cost may be partially balanced by the use of a single agent compared to an antibiotic combination for therapy in some situations, these antibiotics are not cost effective for prophylactic use. Superinfection with fungi, such as\n                    <jats:italic>Candida<\/jats:italic>\n                    , and\n                    <jats:italic>Streptococcus faecalis<\/jats:italic>\n                    have occurred, and toxicities, such as bleeding due to vitamin K deficiency and disulfuram\u2010like reactions, have also been reported. Reports of resistance to moxalactam and the other third generation cephalosporins are of major concern and indicate the need to closely monitor antibiotic susceptibility patterns of hospital acquired organisms if these antibiotics are to be used for empiric therapy of suspected gram negative non\u2010pseudomonas sepsis.\n                  <\/jats:p>","DOI":"10.1002\/j.1875-9114.1982.tb03187.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T11:56:03Z","timestamp":1450266963000},"page":"197-210","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Comparative Evaluation of Moxalactam: Antimicrobial Activity, Pharmacokinetics, Adverse Reactions, and Clinical Efficacy"],"prefix":"10.1002","volume":"2","author":[{"given":"Brian J.","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold C.","family":"Standiford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.1.1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.6.864"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.1.92"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.316"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237999"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.736"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.757"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.302"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.4.503"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.3.297"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.273"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.488"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.2.141"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01639592"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.6.937"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/6.5.607"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.1019"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.3.341"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.3.287"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.5.641"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.412"},{"key":"e_1_2_1_23_2","first-page":"111","article-title":"Antimicrobial activity of a new cephalosporin type antibiotic (moxalactam): increased range for clinical sepsis","volume":"28","author":"Palmer D.","year":"1980","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.1.96"},{"key":"e_1_2_1_25_2","first-page":"287","article-title":"In vitro studies of a novel beta\u2010lactam antibiotic, LY\u2010127935","volume":"27","author":"Watanakunakorn C","year":"1980","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.470"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.516"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.6.747"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/9.suppl_C.41"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/8.suppl_B.33"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.1.130"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.5.716"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-784"},{"key":"e_1_2_1_34_2","unstructured":"LentnekA.Enterococcal superinfection in patients treated with moxalactam (abstract 325). In: Program of the 21 st Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago 1981."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.600"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.129"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.1.51"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.750"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.5.901"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.4.433"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.2.239"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.4.539"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.332"},{"key":"e_1_2_1_44_2","unstructured":"MoodyMR YoungVM SchimpffSC.Synergistic activity of piperacillin\u2010moxalactam\u2010amikacin combinations (abstract 752). In: Program of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans 1980."},{"key":"e_1_2_1_45_2","unstructured":"SchimpffSC.Moxalactam in the treatment of neutropenic patients. In: Symposium on the New Generation Beta Lactam Antibiotics. New Orleans October 20 1981."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.226"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.302"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.6.965"},{"key":"e_1_2_1_49_2","article-title":"Comparative pharmacokinetics of moxalactam, cefoperazone and cefotaxime in normal volunteers","author":"Standiford HC","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.567"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.4.639"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.3.369"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.4.613"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.576"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.3.378"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.33.625"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.15.2.273"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.406"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80562-8"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90505-7"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90240-0"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.218"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.258"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80036-4"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237993"},{"key":"e_1_2_1_66_2","unstructured":"MoutonY CaillauxM BeaucaineGet al.Penetration of moxalactam in bronchial secretions and clinical evaluation in intensive care patients (abstract 732). See reference 33."},{"key":"e_1_2_1_67_2","unstructured":"PolkR SmithJ DuceyKet al.Atrial appendage penetration of moxalactam and cefazolin following simultaneous administration (abstract 734). See reference 33."},{"key":"e_1_2_1_68_2","unstructured":"PolkR HumeA CardeaJ.Comparative bone penetration of moxalactam and cefazolin following simultaneous administration (abstract 736). See reference 33."},{"key":"e_1_2_1_69_2","unstructured":"SmithR SutpherN BaltchAet al.Moxalactam penetration into human prostatic tissue (abstract 737). See reference 33."},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.6.933"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.4.575"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.3.461"},{"key":"e_1_2_1_73_2","first-page":"36","volume-title":"Moxalactam Investigator's Monograph","author":"Lilly Research Laboratories","year":"1981"},{"key":"e_1_2_1_74_2","volume-title":"Moxam package insert","author":"Eli Lilly and Company","year":"1981"},{"key":"e_1_2_1_75_2","unstructured":"PennR PreheimL SandersCet al.Comparison of moxalactam and gentamicin in the treatment of hospitalized patients with acute urinary tract infections (abstract 375). See reference 43."},{"key":"e_1_2_1_76_2","unstructured":"AbbruzzeseJ RoccoL LaskinOet al.Double blind prospective randomized trial of moxalactam and tobramycin in the treatment of urinary tract infections (abstract 315). See reference 33."},{"key":"e_1_2_1_77_2","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/archinte.1981.00340130051014","article-title":"Moxalactam therapy for bacterial infections","volume":"141","author":"Winston D","year":"1981","journal-title":"Arch Int Med."},{"key":"e_1_2_1_78_2","article-title":"Moxalactam versus standard antimicrobial therapy for serious infections","author":"Oblingan M","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_79_2","unstructured":"SabathLD.Clinical experience with moxalactam in the treatment of staphylococcal infections. See reference 44."},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.3.351"},{"key":"e_1_2_1_81_2","article-title":"Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin","author":"DeJongh CA","journal-title":"Am J Med"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.3.535"},{"key":"e_1_2_1_83_2","article-title":"Comparison of moxalactam versus gentamicin\u2010clindamycin in peritoneal and soft tissue surgical sepsis","author":"Stone H","journal-title":"Rev Infect Dis"},{"key":"e_1_2_1_84_2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0002-9378(81)90958-3","article-title":"Moxalactam for obstetric and gynecological infections","volume":"139","author":"Cunningham F","year":"1981","journal-title":"Am J Obstet Gynecol."},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.6.1004"},{"key":"e_1_2_1_86_2","unstructured":"KafetzisD BruchK YoungJ.Cefotaxime in the treatment of purulent meningitis in pediatrics; an overview of published and unpublished data (abstract 457). See reference 33."},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80466-6"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90491-2"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.5.801"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.5.740"},{"key":"e_1_2_1_91_2","unstructured":"MadeJ StovallJ.Treatment of chronic osteomyelitis with moxalactam (abstract 319)."},{"key":"e_1_2_1_92_2","first-page":"38","volume-title":"Hoechst\u2010Roussel Pharmaceuticals, Inc.","year":"1981"},{"key":"e_1_2_1_93_2","unstructured":"KammerRB.Adverse effects associated with moxalactam therapy. See reference 44."},{"key":"e_1_2_1_94_2","unstructured":"BrownA QuesadaO ArmstrongD.Empiric moxalactam therapy in febrile neutropenic patients with cancer on nephrotoxic chemotherapy (abstract 317). See reference 33."},{"key":"e_1_2_1_95_2","unstructured":"FainsteinV EltingL BolivarRet al.Moxalactam and ticarcillin or tobramycin for the treatment of neutropenic cancer patients (abstract 317). See reference 33."},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92693-8"},{"key":"e_1_2_1_97_2","unstructured":"WoldJ BueningM.Alcohol\u2010moxalactam interactions in vivo. In: Symposium on the New Generation of Beta\u2010lactam Antibiotics. London England;1981 May 78."},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.1.88"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.3.476"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.470"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80559-8"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80562-8"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80036-4"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-3-302"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80015-7"},{"key":"e_1_2_1_106_2","unstructured":"KeyserlingH FeldmanWE MoffittSet al.Clinical and pharmacological evaluation of moxalactam in pediatric patients. In: Program of 21st Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 321). Chicago November 1981."},{"key":"e_1_2_1_107_2","unstructured":"YogevR SchreiberM GardnerSet al.Moxalactam in pediatric infections (abstract 322). See reference 8."},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.3.476"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.470"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80559-8"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80562-8"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80036-4"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-3-302"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80015-7"},{"key":"e_1_2_1_115_2","unstructured":"KeyserlingH FeldmanWE MoffittSet al.Clinical and pharmacological evaluation of moxalactam in pediatric patients. In: Program of 21st Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 321). Chicago November 1981."},{"key":"e_1_2_1_116_2","unstructured":"YogevR SchreiberM GardnerSet al.Moxalactam in pediatric infections (abstract 322). See reference 8."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03187.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03187.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1982.tb03187.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:57:25Z","timestamp":1761047845000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1982.tb03187.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,7,8]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1982,7,8]]}},"alternative-id":["10.1002\/j.1875-9114.1982.tb03187.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1982.tb03187.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,7,8]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}